Vaccine clinical trials pose unique challenges with regards to duplicate research subjects or professional subjects.

Typically, large numbers of subjects are dosed at the first visit. There is no way for a site or principal investigator to adequately check if the research subject is a duplicate or professional subject. Subjects are dosed multiple times, causing safety issues as well as problems with the placebo response.  This can result in a clinical trial failure.

Verified Clinical Trials a global research subject database registry provides a cross-study and cross-sponsor solution to detecting and preventing duplicate subjects. VCT protects phase I through phase IV studies and has global dedicated support.

The detection occurs just at the time of screening, preventing, costly in eligible poor-quality subjects from joining the clinical trial. The protections continue the entire duration of the study, improving retention as well as research, subject, safety, and data quality.

Verified Clinical Trials also prevents numerous other potential protocol violations that help your clinical trial achieve success.

This is why the majority of the largest vaccine developers in the world have turned to Verified Clinical Trials to protect their studies and improve outcomes.

VCT operates globally and has a patented solution that is unlike any other solution in the industry.